Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

ee and twelve months ended December 31, 2009, respectively. Revenues totaled $44,000 and $0.3 million for the three- and twelve-month periods ended December 31, 2008, respectively. The revenues earned during 2009 resulted from the recognition of a portion of the upfront, non-refundable license fee and reimbursement of third-party development costs under our license agreement with Bayer. The $35.0 million upfront license fee has been recognized on a straight-line basis over a period of approximately 13 months, which was the original period in which we expected to complete all of our obligations under the license agreement with Bayer. In December 2009, we revised our estimate of this period extending it to 26 months as a result of design modifications to our ongoing RDEA119 clinical trials. The unamortized balance of the license fee as of the date of the change in estimate will be recognized over the revised timeline. The revenue earned in fiscal 2008 resulted from the research services we provided under our master services agreement with Valeant, which has since terminated by its terms.

The net loss applicable to common stockholders for the three and twelve months ended December 31, 2009 was $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively, compared to a net loss applicable to common stockholders for the same periods in 2008 of $12.7 million and $5
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Vista Partners announced today that it has ... "Company") and raised its twelve month target price to AUD ... is on track to enter clinical trials for its AMI ... The Company recently completed humanisation of its "first in class" ...
... of brand drug "copay coupon" promotions, which lure insured ... costs by $681 million in Missouri over the next ... to new research from Visante and released by the ... of these promotions by state and local government workers ...
Cached Medicine Technology:Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $681 Million in Missouri 2
(Date:4/14/2014)... NJ. April 10, 2014. John DeLuca, PhD, and Yael ... Idec to study how persons with multiple sclerosis (MS) ... of Actual Reality to Measure Everyday Life Functional Activity ... research. Dr. DeLuca is senior VP of Research & ... at New York University, is a visiting scientist at ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... COLUMBUS, Ohio A new study identifies a molecule ... and suggests that the molecule could be an important ... of tumor progression. , The study of microRNA-135b (miR-135b) ... in the journal Cancer Cell and was ... Cancer Center Arthur G. James Cancer Hospital and ...
(Date:4/14/2014)... --- Depression can hit young fathers hard -- with symptoms ... their children,s lives, a new Northwestern Medicine study has found. ... the first five years of fatherhood for these young men, ... and whom lived in the same home as their children. ... the journal Pediatrics . , This study is the ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... 14 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ... Drug,Administration (FDA) has granted final approval for the ... Tablets, "over-the-counter", (OTC), 5 mg and 10 mg ... be marketed as two separate OTC,products in two ...
... widens, the concerns about oversight deepen , , , First ... ever before, Americans are worried about the safety of the ... reason. , In little less than a year and a ... own peculiar food pyramid: meats, vegetables, salad, snacks, fast food, ...
... from Life Coach Laura Berman Fortgang -, NEW YORK, ... fresh starts and changing for the better. Internationally recognized,life coach, ... resolutions and stick with them throughout the year. With Laura,s,tips ... is,sure to start brightly., "Make a New Year,s resolution ...
... the sound they make is an important survival skill and ... objects can physically make very dissimilar sounds and we are ... source of the sound. Scientists funded by the Biotechnology and ... human ear and the brain come together to help us ...
... LDL levels influence heart disease risk , , SUNDAY, Jan. ... which influence the risk of heart disease, have been ... in three countries. , "I would predict that some ... drugs," said the study,s senior author, Goncalo Abecasis, an ...
... "Without notMYkid, I,wouldn,t be here today," says James, ... didn,t know, as long as I was at dinner ... share my story,with kids today and prevent them from ... thrilled that a partnership between Chrysler LLC and,Barrett- Jackson ...
Cached Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Children's Zyrtec(R) Chewable Tablets for Allergy Relief and Children's Zyrtec(R) Chewable Tablets for Hives Relief 2Health News:U.S. Food Safety: Home-Grown Problems Abound 2Health News:U.S. Food Safety: Home-Grown Problems Abound 3Health News:U.S. Food Safety: Home-Grown Problems Abound 4Health News:U.S. Food Safety: Home-Grown Problems Abound 5Health News:U.S. Food Safety: Home-Grown Problems Abound 6Health News:Smile! Make Your New Year's Resolutions a Reality This Year 2Health News:Smile! Make Your New Year's Resolutions a Reality This Year 3Health News:Lend me your ears -- and the world will sound very different 2Health News:Seven New Cholesterol Genes Discovered 2Health News:Seven New Cholesterol Genes Discovered 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2
... Technology, multi-frequency, linear micro-surgery transducer. ... very helpful in tight situations. ... a choice transducer for pediatric ... high frequency upper end makes ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
Medicine Products: